Neuromelanin, neuroleptics and schizophrenia: hypothesis of an interaction between noradrenergic and dopaminergic system
Related Experiment Video
Updated: Oct 27, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Abstract:
On the assumption that neuromelanin content might be a parameter indicating neuronal activity in the catecholaminergic system, neuromelanin was measured microspectrophotometrically in the substantia nigra and the locus ceruleus of 12 brains of patients who had undergone neuroleptic therapy. Neuromelanin increased with age in both regions of 40 control brains. Although no significant difference in melanin content between medicated and control brains was seen, a high negative correlation (r = -0.79) was noted in melanin content between the substantia nigra and the locus ceruleus only in each medicated brain, especially in cases of schizophrenia. The possibility of noradrenergic and dopaminergic interaction is discussed.
More Related Videos
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Antipsychotic Drugs: Typical and Atypical Agents
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

